Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...
The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose of dual immune checkpoint blockade (ICB) before standard chemoradiation is a ...
Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results